Day One Biopharmaceuticals Inc.’s recently made public that its Chief Executive Officer Bender Jeremy unloaded Company’s shares for reported $41525.0 on Aug 17. In the deal valued at $13.86 per share,2,996 shares were sold. As a result of this transaction, Bender Jeremy now holds 704,224 shares worth roughly $ 9.84 million.
Then, York Charles N II sold 922 shares, generating $12,779 in total proceeds. Upon selling the shares at $13.86, the COO, CFO and Secretary now owns 267,501 shares.
Before that, Blackman Samuel C. sold 668 shares. Day One Biopharmaceuticals Inc. shares valued at $9,258 were divested by the Head of Research and Developme at a price of $13.86 per share. As a result of the transaction, Blackman Samuel C. now holds 1,236,319 shares, worth roughly $17.27 million.
BofA Securities downgraded its Day One Biopharmaceuticals Inc. [DAWN] rating to an Underperform from a a Buy in a research note published on Friday, April 25, 2023; the price target was decreased to $9 from $34. PT values the company’s stock at a premium of -55.22 to its Friday closing price.
Price Performance Review of DAWN
On Friday, Day One Biopharmaceuticals Inc. [NASDAQ:DAWN] saw its stock jump 3.56% to $13.97. On the same session, the stock had its day’s lowest price of $13.51, but rose to a high of $14.17. Over the last five days, the stock has lost -0.36%. Day One Biopharmaceuticals Inc. shares have fallen nearly -35.08% since the year began. Nevertheless, the stocks have fallen -40.53% over the past one year. While a 52-week high of $26.72 was reached on 01/09/23, a 52-week low of $10.84 was recorded on 04/25/23. SMA at 50 days reached $12.71, while 200 days put it at $16.26. A total of 0.6 million shares were traded, compared to the trading of 0.81 million shares in the previous session.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 13.60, which if violated will result in even more drops to 13.22. On the upside, there is a resistance level at 14.26. A further resistance level may holdings at 14.54. The Relative Strength Index (RSI) on the 14-day chart is 59.13, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 25.00%. Stochastics %K at 51.21% indicates the stock is a holding.
How much short interest is there in Day One Biopharmaceuticals Inc.?
A steep rise in short interest was recorded in Day One Biopharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -1.57 million shares to a total of 12.07 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 13.64 million shares. There was a decline of -13.01%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 21.96% of the overall stock float, the days-to-cover ratio (short ratio) fell to 18.88.
Day One Biopharmaceuticals Inc. [DAWN] – Who Are The Largest Shareholders?
In filings from RA Capital Management LP, it is revealed that the company now owns 7,809,852 shares, or roughly 8.98% of the outstanding DAWN shares. In other words, the investor’s shares have risen by 769,230 from its previous 13-F filing of 7040622.0. Additionally, Fidelity Management & Research Co increased 10.24% of its stake after which the total value it holdings stand at $81,243,884, while The Vanguard Group, Inc. added 34.00% of its stake to hold $55.1 million in the firm. Over the last quarter, Franklin Advisers, Inc. purchased 652,697 shares of Day One Biopharmaceuticals Inc., while Braidwell LP bought 201,918 shares. At present, SSgA Funds Management, Inc. is holding 3,354,326 shares valued at $44.41 million. BlackRock Fund Advisors owned 3,235,332 shares of the company at the time of its most recent 13F filing, worth $42.84 million.